|
|
Article: GENEMEDICINE Receives Broad Patent Covering the Use of Cationic Lipids for Gene Therapy.
- Article from:
- Business Wire
- Article date:
- October 15, 1997
CopyrightCOPYRIGHT 1997 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
THE WOODLANDS, Texas--(BW HealthWire)--October 15, 1997--
Worldwide exclusive license to Vanderbilt University patent issued in U.S. and in Europe covers widely used non-viral gene delivery technology
GENEMEDICINE, INC. (NASDAQ:GMED) announced today the issuance both in the U.S. and in Europe of a major gene therapy patent. The patent claims broadly cover the use for gene therapy of any cationic lipid combined with DNA and administered by injection or inhalation, the most common routes of administration.
Cationic lipids are widely used in non-viral gene therapy. Numerous published studies have demonstrated the capability of cationic ...